Table 4. Treatments and Outcomes Among Patients With Low-Grade Stage Ta Non–Muscle-Invasive Bladder Cancer.
| Treatment or outcome | Patients, No. (%) (N = 13 054) |
|---|---|
| BCG | |
| No | 10 804 (82.8) |
| Yes | 2250 (17.2) |
| Intravesical chemotherapya | |
| No | 12 262 (93.9) |
| Yes | 792 (6.1) |
| TURBT | |
| No | 1344 (10.3) |
| Yes | 11 710 (89.7) |
| Recurrenceb | |
| No | 12 837 (98.3) |
| Yes | 217 (1.7) |
| Progressionc | |
| No | 13 002 (99.6) |
| Yes | 52 (0.4) |
| Systemic chemotherapy | |
| No | 13 018 (99.7) |
| Yes | 36 (0.3) |
| Radical cystectomy | |
| No | >13 040 (99.9) |
| Yes | <11 (0.1)d |
| Radiotherapy | |
| No | >13 040 (99.9) |
| Yes | <11 (0.1)d |
| Death associated with bladder cancer | |
| No | 12 680 (97.1) |
| Yes | 374 (2.9) |
| Death associated with other causes | |
| No | 8662 (66.4) |
| Yes | 4392 (33.6) |
Abbreviations: BCG, bacillus Calmette-Guérin; TURBT, transurethral resection of bladder tumor.
a
Beyond receipt of a single perioperative dose.
b
Includes any patient who received TURBT more than 3 months after index diagnosis without disease progression.
c
Defined as any patient who received definitive treatment for bladder cancer.
d
Exact values for variables pertaining to fewer than 11 patients could not be reported in accordance with reporting guidelines from the Surveillance, Epidemiology, and End Results program.